Cancer Medicine · 2022 · 17 citations · 18 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyTumor ProgressionCancer ProgressionLung CancerNext-generation Sequencing In OncologyReceptor Tyrosine Kinase OncogenesTyrosine Kinase InhibitorsAlk Fusion GenesAlk Point MutationsAlk Rearrangement TestingAnaplastic Lymphoma Kinase InhibitionAnaplastic Lymphoma Kinase InhibitorsNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentTherapeutic Tyrosine Kinase Inhibitors
BACKGROUND: Anaplastic lymphoma kinase (ALK) fusion is a prognostic indicator for patients with non-small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real-world data of ALK TKIs remain a major concern. METHODS: Patients with ALK-positive advanced NSCLC, who received crizotinib or alectinib treatment in first line, were retrospectively reviewed. ALK status was detected using immunohistochemistry (IHC) or next-generation sequencing (NGS). Clinical outcomes have been comprehensively analyzed between TKIs, ALK fusions, EML4-ALK variants, and next-generation TKIs after crizotinib failure. RESULTS: One hundred sixty-eight patients were successively enrolled (crizotinib, n = 109; alctinib, n = 59). Alectinib showed consistent superiority in progressive-free survival (PFS) over crizotinib (hazard ratio [HR]: 0.43, 95% confidential interval [CI]: 0.24-0.77, p = 0.004). Multivariate Cox regression showed chemotherapy (CT) prior to TKIs or synchronous chemotherapy seemed not to improve PFS compared to ALK inhibitors alone (p > 0.05). And, alectinib was superior to crizotinib in prolonging intracranial PFS (HR 0.12, 95% CI: 0.03-0.49, p = 0.003). Patients in EML4 group had a better prognosis than those in non-EML4 group after alectinib administration (HR 0.13, 95% CI: 0.03-0.60, p = 0.009). TP53 co-mutations were relatively common (34.0%) and associated with adverse outcome in ALK-positive patients (adjusted HR 2.22, 95% CI: 1.00-4.92, p = 0.049). After crizotinib failure, 33 patients received a sequential application of next-generation ALK TKIs. Compared to ceritinib and brigatinib, alectinib might have better PFS (p = 0.043). CONCLUSION: Our results revealed alectinib had better PFS and higher intracranial efficacy compared to crizotinib in ALK-positive NSCLC, and might improve PFS by comparison with ceritinib and brigatinib after crizotinib failure.
18
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +12
Tony Mok, D. Ross Camidge, Shirish M. Gadgeel et al. · Annals of Oncology · 2020 · 686 citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Alice T. Shaw, Tae Min Kim, Lucio Crinò et al. · The Lancet Oncology · 2017 · 580 citations · Full text
Medicine, Oncology, Pharmacology +12